Increased risk for vascular complications in PRV‐1 positive patients with essential thrombocythaemia

Peter Johansson(Linköping University), Björn Andréasson(NU Hospital Group), Jack Kutti(Sahlgrenska University Hospital), Lars Palmqvist(Sahlgrenska University Hospital), Anne Ricksten(Sahlgrenska University Hospital), Lovisa Wennström(Sahlgrenska University Hospital)
British Journal of Haematology
October 20, 2003
10.1046/j.1365-2141.2003.04634.x
Cited by 30

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
|Blood|2014|153